CTKB Q4 2023 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q4 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$58M+20.5% YoY

Gross Profit

$33M56.8% margin

Operating Income

-$137,000-0.2% margin

Net Income

$6M9.4% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+21.3%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$8M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$494M

Total Liabilities

$101M

Stockholders' Equity

$393M

Cash & Equivalents

$167M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$48M	+20.5%
Gross Profit	$33M	$29M	+12.5%
Operating Income	-$137,000	$84,000	-263.1%
Net Income	$6M	$4M	+55.9%

Revenue Segments

Product

$47M100%

Geographic Segments

UNITED STATES

$24M41%

EMEA

$21M36%

Asia Pacific

$12M20%

Other

$2M3%